Biosimilar medicines uptake: The role of the clinical pharmacist

Okoro, Roland Nnaemeka

doi:10.1016/j.rcsop.2021.100008

Cited by 12 publications

(17 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, when considering education, clinical pharmacists have a broad understanding of the clinical, logistical, and supply chain aspects of biosimilars; thus, they can also be valuable assets in educating stakeholders, such as prescribers, formulary committee members, other pharmacists, nurses, administrative personnel, and patients, around biosimilars in an effort to improve access and rational usage [ 66 ].…”

Section: Discussionmentioning

confidence: 99%

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

et al. 2022

View full text Add to dashboard Cite

Background Multiple switches (transitions) between biosimilars of the same reference biologic are now a reality, and they are expected to become more common in the future as more biosimilars enter the market. Switching between two biosimilars of the same reference biologic is generally driven by affordability, formulary requirements, or the relocation/travel of the patient. Evidence of whether switching between biosimilars of the same reference biologic provides similar safety and efficacy profiles is reviewed here. Methods A systematic search was undertaken using electronic databases (to December 2021): Biosis, Embase, MEDLINE, and EBM Reviews/Cochrane Database of Systematic Reviews via Ovid. Publications were evaluated for effectiveness and/ or safety data linked to switching from one biosimilar to another. ResultsThe systematic search yielded 982 citations. After eliminating duplicates, 626 citations remained for the initial title/ abstract screening phase. Following the initial screening, 240 records were chosen; more thorough examination yielded 35 citations. After comprehensive screening and expert advice, 23 studies were selected, of which 13 were published in peerreviewed journals; the remainder have been published as abstracts. Overall, 3657 patients were included in these studies. All studies were observational in nature; no randomized clinical trials were identified. The studies were heterogeneous in size, design, and endpoints. Across the studies, data are provided on safety, effectiveness, immunogenicity, pharmacokinetics, patient retention, patient and physician perceptions, and drug-use patterns. The majority of studies examined switches between biosimilar infliximabs, although switches between biosimilar adalimumabs, etanercepts, and rituximabs were also identified. Two use-pattern studies and one case report were also detected and are discussed. Conclusion Within the limitations of this systematic review, available data suggests that biosimilar-to-biosimilar switching is a safe and effective clinical practice, although it is not covered by current health authority regulations or guidance. No reduction in effectiveness or increase in adverse events was detected in biosimilar-to-biosimilar switching studies conducted to date.

show abstract

Section: Discussionmentioning

confidence: 99%

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Halabi et al stated that the approval and use of biosimilars must be supported by scientifically sound evidence and that educational resources should be provided to healthcare professionals and patients [16]. Okoro reported that as biosimilars differ from generic medicines, it is imperative that healthcare specialists involved in their use have adequate critical information about their prescribing practices, interchangeability and traceability and that physicians may require additional information from clinical pharmacist s to make a decision about biosimilar use [17].…”

Section: Resultsmentioning

confidence: 99%

Physicians' Opinions on the Required Information about Biosimilars and the Need for Biosimilars Related Education

Ahmed

2021

JPRI

View full text Add to dashboard Cite

Aim: The aim of this study was to investigate physicians' opinions on the required information about biosimilars and the need for biosimilars related education. Methodology: The study included a survey that was prepared using a survey from a previous study and after face validation and content validation, it was prepared as an online form using the SurveyMonkey platform. Results: The majority of physicians stated that the most important information about biosimilars are studies that provide clinical immunogenicity data for the biosimilar and reference product (93.33%) in addition to studies that directly compare clinical efficacy and safety between reference products and biosimilars (88.89%). The majority of physicians stated that tracking safety events with biosimilars (94.45%) and access to information on studies comparing biosimilars with reference biologics (91.11%) are important issues related to biosimilars in professional environments. Conclusion: The present study highlights the needs of physicians for biosimilar education. More efforts are needed to increase the awareness regarding biosimilars by different formats in order to integrate biosimilars into clinical practice and to counsel patients about biosimilars.

show abstract

“…Most biosimilar preparations are registered in such areas as oncology or dermatology and nurses working in those fields turned out to be most knowledgeable about these drugs. Biosimilars have been on the market for approximately 1.5 decades [ 23 , 24 ]. An astonishing fact is that in our study, older nurses declared greater knowledge about these drugs, even though they certainly did not get this knowledge from their studies’ curriculum.…”

Section: Discussionmentioning

confidence: 99%

Nurses’ Knowledge and Attitudes towards Biosimilar Medicines as Part of Evidence-Based Nursing Practice—International Pilot Study within the Project Biosimilars Nurses Guide Version 2.0

Friganović

Mędrzycka‐Dąbrowska

Krupa

et al. 2022

IJERPH

View full text Add to dashboard Cite

Introduction: The increasing availability of biosimilars can increase patient access to these drugs and reduce the economic burden. Nurses play a key role in the education, administration, pharmacovigilance and management of the side effects of biosimilars. The aim of this study was to assess the knowledge and attitudes of nurses towards biosimilar drugs in different countries. Methods: An international cross-sectional study was conducted from November 2021 to February 2022. The survey was carried out using Computer-Assisted Web Interview (CAWI), sent by the CAWI panel via the website. Results: The results showed that nurses with a greater level of education felt most knowledgeable about biosimilars (χ2 = 105.813, df = 2, p < 0.001). One-third of nurses with a doctorate and a second degree said biosimilars are used in their workplace (χ2 = 48.169, df = 4, p < 0.001); most nurses with a second degree said that they had never heard of biosimilars (41%). Doctorate-level nurses thought knowledge is the key factor to increasing biosimilar uptake (97%). Conclusions: Nurses are not knowledgeable about biosimilars. Most would like to participate in training on biosimilars. This is a very important topic, because biosimilars are constantly evolving in medicine.

show abstract

Biosimilar medicines uptake: The role of the clinical pharmacist

Cited by 12 publications

References 22 publications

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

Physicians' Opinions on the Required Information about Biosimilars and the Need for Biosimilars Related Education

Nurses’ Knowledge and Attitudes towards Biosimilar Medicines as Part of Evidence-Based Nursing Practice—International Pilot Study within the Project Biosimilars Nurses Guide Version 2.0

Contact Info

Product

Resources

About